Roth Positive on MEI Pharma (MEIP) Following ME-344 Phase 1b Initiation
Tweet Send to a Friend
Roth Capital reaffirms its Buy rating and $20 price target on MEI Pharma, Inc. (Nasdaq: MEIP) following news earlier that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
